drugset / Trial / NCT03933319
Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer
Phase 2
Unknown
30 enrolled
Chinese Academy of Medical Sciences
CSPC Ouyi Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center phase Ⅱ study designed to evaluated the efficacy and safety of pegylated liposomal doxorubicin（PLD）in combination with trastuzumab in HER-2 positive metastatic breast cancer .
Timeline
- Start
- 2019-03-11
- Primary completion
- 2021-03-31
- Completion
- 2022-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegylated liposomal doxorubicin | Unknown | 35 mg/m2 | Intravenous |